Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Gender-affirming hormone therapy changes hair growth in transgender people, with feminizing therapy reducing hair and masculinizing therapy increasing it, but sometimes additional treatment is needed.

Enzymes called 5α-reductases have many body functions and need more research to safely use inhibitors.

Serenoa repens may help treat hair loss but is less effective than common medications and needs more research to confirm its effectiveness.

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

IL-6 contributes to hair loss by shortening the growth phase and causing hair follicles to regress.

A substance called DKK-1 increases in balding areas and causes hair cells to die when exposed to DHT.

Both drugs lower DHT levels, with GI198745 being more effective.

Finasteride reduces scalp DHT levels, potentially treating male pattern baldness.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.

Testosterone boosts red blood cell production and changes iron metabolism without needing dihydrotestosterone.

Blocking a specific enzyme in male rat fetuses leads to the development of nipples and feminized genitalia.

Understanding how DHT works is important for diagnosing and treating hormone-related disorders.

Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.

The 0.25% finasteride solution, when applied once a day, effectively reduces scalp DHT, potentially minimizing sexual side-effects linked to a systemic DHT reduction.

MK-386 lowers DHT in blood and skin but not in semen.

Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.

DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.

DHT deficiency in rats reduces sperm content and affects testis structure over time.

Dihydrotestosterone (DHT) stops hair growth in mice by lowering a growth factor important for hair.

Dihydrotestosterone increases certain inflammatory signals in skin cells, potentially contributing to acne.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

DHT deficiency increases iNOS expression in rat testis and epididymis.

The normal human prostate does not significantly affect blood DHT levels.

Male cells need DHT to respond to testosterone, while female cells do not.

Finasteride changes androgen receptor location in rat epididymis without altering tissue structure.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

DHT stops hair regrowth in mice, similar to human hair loss.